Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program
Company Acquires Phase… [+10336 chars]
Insmed Provides Clinical and Business Update - Insmed Incorporated Investor Relations
—Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program— —Company...
Source:Insmed.com
Published:
Related News
Column | I let ChatGPT analyze a decade of my Apple Watch data. Then I called my doctor. - The Washington Post
I gave the new ChatGPT Health access to 29 million steps and 6 million heartbeat measurements. It drew questionable conclusions that changed each time I asked.
The Washington Post•Geoffrey A. Fowler
Opinion | An old problem could stop the U.S. from leading on quantum computers - The Washington Post
The winner of the race for the futuristic tech could be determined by supply-chain bottlenecks.
The Washington Post•Chris Miller, Josh Zoffer
Quantum Computing Stocks: IonQ To Acquire SkyWater In $1.8 Billion Deal - Investor's Business Daily
IonQ, the most aggressive acquirer among quantum computing stocks, agreed to buy SkyWater for $1.8 billion in a cash and stock deal.
Investor's Business Daily